In the US, Vincasar PFS (vincristine systemic) is a member of the drug class mitotic inhibitors and is used to treat Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Anaplastic Oligodendroglioma, Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Neuroblastoma, Non-Hodgkin's Lymphoma, Rhabdomyosarcoma and Wilms' Tumor.
Ingredient matches for Vincasar PFS
Vincristine sulfate (a derivative of Vincristine) is reported as an ingredient of Vincasar PFS in the following countries:
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.